Silverberg Bernstein Capital Management LLC Invests $1.46 Million in Johnson & Johnson (NYSE:JNJ)

Silverberg Bernstein Capital Management LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,300 shares of the company’s stock, valued at approximately $1,458,000. Johnson & Johnson comprises 1.4% of Silverberg Bernstein Capital Management LLC’s investment portfolio, making the stock its 18th largest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co boosted its holdings in Johnson & Johnson by 0.6% in the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after purchasing an additional 414 shares during the last quarter. OneAscent Financial Services LLC lifted its holdings in Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after buying an additional 4,457 shares during the last quarter. TrueMark Investments LLC bought a new position in Johnson & Johnson during the 4th quarter worth approximately $1,458,000. RAM Investment Partners LLC lifted its holdings in Johnson & Johnson by 4.5% during the 4th quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock worth $265,000 after buying an additional 73 shares during the last quarter. Finally, RFG Advisory LLC lifted its holdings in Johnson & Johnson by 12.6% during the 3rd quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock worth $2,921,000 after buying an additional 2,102 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 28th. Morgan Stanley reduced their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Stock Up 1.4 %

JNJ opened at $157.96 on Thursday. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The stock has a market cap of $380.65 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. The stock’s 50 day moving average price is $158.76 and its 200 day moving average price is $156.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same period last year, the firm earned $2.35 EPS. The firm’s revenue was down 9.7% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.